Bliss Biopharmaceutical

Eisai Pays up to $2B for ADC Bearing Its Halaven as Payload
BioSpace
Tue, 05/9/23 - 11:07 am
Eisai
Bliss Biopharmaceutical
clinical trials
antibody-drug conjugate
Halaven